Brief: Kaleido Biosciences Initiates Controlled Clinical Study Of Microbiome Metabolic Therapy Kb109 In Outpatients With Mild-To-Moderate COVID-19

Kaleido Biosciences

14/05/2020 11:41

May 14 (Reuters) - Kaleido Biosciences Inc  KLDO.O :
    * KALEIDO BIOSCIENCES INITIATES CONTROLLED CLINICAL STUDY OF
MICROBIOME METABOLIC THERAPY KB109 IN OUTPATIENTS WITH
MILD-TO-MODERATE COVID-19
    * KALEIDO BIOSCIENCES INC - TOP-LINE DATA FROM STUDY OF
APPROXIMATELY 350 PATIENTS EXPECTED IN Q4 2020
    * KALEIDO BIOSCIENCES INC - SECOND CLINICAL STUDY EXPECTED
TO
INITIATE SHORTLY WITH SIMILAR DESIGN AND ADDITIONAL MICROBIOME
ANALYSIS

Source text for Eikon:  ID:nGNX3jGYHp 
Further company coverage:  KLDO.O 

 ((Reuters.Briefs@thomsonreuters.com;))